Periocular infantile haemangioma and the role of propranolol. by Chaudhry, Tanveer Anjum et al.
eCommons@AKU
Department of Surgery Department of Surgery
August 2013
Periocular infantile haemangioma and the role of
propranolol.
Tanveer Anjum Chaudhry
Aga Khan University, tanveer.chaudhry@aku.edu
Mustafa Kamal
Aga Khan University, mustafa.kamal@student.aku.edu
Khabir Ahmad
Agha Khan University, khabir.ahmad@aku.edu
Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_surg
Part of the Ophthalmology Commons
Recommended Citation
Chaudhry, T., Kamal, M., Ahmad, K. (2013). Periocular infantile haemangioma and the role of propranolol.. JCPSP: J Coll Physicians
Surg Pak., 23(8), 593-595.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/175
INTRODUCTION
Capillary haemangiomas are the most common child-
hood eye tumours (periocular and orbital) that typically
appear in infancy but most tend to decrease in size
overtime.1 Periocular haemangiomas are 3 times more
common among females than males, and can be
familial. They can cause refractive and occlusive
amblyopia if not treated timely. Most of these tumours
regress completely without any residual evidence in 3 to
7 years time. The reddish lesion slowly changes to gray
colour and the surface epithelium slowly changes to a
more normal skin appearance with thin and wrinkled
texture. These changes are associated with skin
hypotrophy. Oral steroids and intra-lesional steroid
injections are the most common treatment options for
such haemangioma.2 However, there is no standard
treatment for these lesions. Propranolol is a new and
effective addition to its treatment.3-5
It is postulated that basic fibroblast growth factor, also
known as bFGF and vascular endothelial growth factor
(VEGF) are responsible for the development and
persistence of infantile haemangiomas. Propranolol
produces initial vasodilatation and relieves ischaemia of
the affected area. Therefore, it reduces the expression
of genes responsible i.e. bFGF and VEGF by down
regulating Raf-mitogen-activated protein kinase pathway
resulting in constriction of pre-capillary sphincters, thus
blocking blood flow to the capillaries and gradual
resolution of the lesion.
Below is the first report of propranolol use for the
treatment of periocular haemangiomas in our country.
CASE REPORT
A two and a half-month-old girl was brought to the eye
clinic of the Aga Khan University Hospital, Karachi with
a history of having developed a red-coloured lesion
around the left upper eyelid at one week of age. There
was a large left periocular swelling covering the entire
upper eyelid. However, she was able to open her left eye
enough to reveal her pupil and the red reflex (Figure 1).
The swelling was purple in colour, with smooth
compressible surface. Valsalva maneuver resulted in
enlargement of the swelling. The other eye and its
periocular area were normal. The baby was following
light and fixating on objects, with normally reacting
pupils. She was kept under observation, but by the age
of four and a half months, the swelling had increased
enough to cover her visual axis and completely occlude
her left eye.
Before starting of treatment, an informed consent was
obtained from the parents of the patient. Her pre-
treatment physical examination, laboratory work-up,
chest X-ray and ECG were normal. Magnetic resonance
imaging (MRI) brain and orbits were advised but were
refused by the parents.
She was hospitalized under the care of a paediatrician
and oral propranolol therapy initiated with a daily dosage
of 1 mg/kg body weight. The dose was slowly increased
to 4.5 mg/kg body weight/day (in three divided doses)
over the next few days. Her blood pressure and
respiratory rates were monitored. Her blood sugar was
also measured daily to monitor propranolol-related
hypoglycaemia. While there was very little response to
this therapy in the first two weeks, there was a marked
response at 1 month. Prednisolone with dose of 2 mg/kg
body weight/day was added for a short period (6 weeks)
to accentuate reduction in the size of haemangioma but
was gradually reduced and eventually stopped due to its
side effects such as weight gain, puffiness, gastric
upset, skin eruptions on back and thighs, polyphagia,
polydipsia and polyuria. She was examined on a
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monthly basis. Two months after the initiation of
treatment, she could open her affected eye only slightly.
Three and a half months later, she was able to open her
eye well enough to reveal more than half of the cornea
(Figure 2). At 8 months, the response to therapy was
excellent with complete eye opening and only a small
remnant of haemangioma (Figure 3). There were no
significant propranolol-related adverse events except
one episode of difficulty in breathing which resolved
within couple of days.
DISCUSSION
Currently, there is no standard treatment for haeman-
giomas. In 2008, Leaute-Labreze first described the role
of propranolol for the treatment of severe haeman-
giomas of infancy.6 Since then, there has been a great
interest in the use of propranolol for the treatment for
infantile haemangiomas. Propranolol alone or in
combination with existing treatment modalities such as
steroids is being explored as a new and effective
treatment option.
We treated the child with propranolol and response to
the therapy was excellent. An almost complete reduction
in size of haemangiomas was achieved after 8 months
of treatment with only a small, flat remnant of it left.
There was complete eye opening. The standard dose of
propranolol for the treatment of infantile periocular
haemangiomas has not been defined to-date. Previous
investigators have reported successful outcomes with
dozes ranging from 1 mg/kg body weight to 5mg/kg body
weight.7 This child was treated with propranolol therapy
beginning at a dose of 1 mg/kg body weight/day and
slowly increasing to 4.5 mg/kg body weight/day over the
next few days. The child was regularly monitored by a
paediatrician for any adverse event. Only one episode of
difficulty in breathing was observed which resolved
within couple of days. We recommend that drug should
only be given when its benefits outweigh its known risks.
A limitation of this case report is that it was unclear if this
haemangiomas involved the orbit. MRI orbits were
advised but were refused by the parents.
To the best of authors’ knowledge, this is the first
reported use of propranolol in the treatment of periocular
haemangiomas in Pakistan. This case report as well
as many other illustrate the advantages of this medicine
in the treatment of periocular haemangiomas. The
therapeutic use of propranolol is important as it
minimizes the need for systemic steroid, resulting in
minimum side effects. Moreover, its use is likely to
reduce the need for any surgical intervention.
Periocular haemangiomas are relatively uncommon
conditions. Although self-limiting in many cases, it may
leave permanent blemish which may be associated with
stress and anxiety for the parents. Effective treatment is
important to minimize the potential for blemish in
cosmetically important anatomic sites, and to minimize
the risk of functional visual deficit. 
At present, there has been no consensus regarding
what should be the dose and duration of propranolol
treatment for this condition. Large randomized trials are
needed to determine whether treating periocular
haemangiomas with propranolol is effective.
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Figure 1: Before the initiation of treatment with
propranolol.
Figure 3: Eight months after the initiation of
treatment with propranolol.
Figure 2: Three and a half months after the
initiation of treatment with propranolol.
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